GlassScriptPhysician profile
Stacie Schuerman
NPI 1598213720
$1,267.65
in general payments reported to CMS, 2019-2025
34 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $152 · 2023: $762 · 2024: $13.23 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.13 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $136.27 | 2023 | Imbruvica, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $89.35 | 2022-2023 | Imbruvica |
| Amgen INC. | $84.45 | 2021-2022 | |
| Genzyme Corporation | $80.16 | 2021-2023 | |
| Incyte Corporation | $76.11 | 2022-2023 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $74.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $67.01 | 2023-2025 | Tagrisso |
| Merck Sharp & Dohme LLC | $65.92 | 2023 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $63.16 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $63.14 | 2021-2025 | Opdivo, Reblozyl |
| Taiho Oncology, INC. | $36.65 | 2022-2023 | |
| Foundation Medicine, INC. | $30.72 | 2023 | Foundationone Liquid Cdx |
| G1 Therapeutics, INC. | $28.66 | 2023 | Cosela |
| Celgene Corporation | $27.48 | 2022-2024 | Pomalyst |
| Blueprint Medicines Corporation | $24.57 | 2023 | Ayvakit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $21.60 | 2023 | Libtayo |
| Amag Pharmaceuticals, INC. | $21.58 | 2021 | |
| Acceleron Pharma, INC. | $21.57 | 2021 | |
| Emd Serono, INC. | $21.48 | 2023 | Tepmetko |
| Eisai INC. | $20.96 | 2023 | |
| Genmab U.S., INC. | $20.78 | 2023 | Tivdak |
| Array Biopharma INC | $20.36 | 2023 | Mektovi, Braftovi |
| Daiichi Sankyo INC. | $18.73 | 2022 | |
| Adc Therapeutics America, INC. | $16.66 | 2023 | |
| Gilead Sciences, INC. | $15.68 | 2023 | |
| Sumitomo Pharma America, INC. | $15.22 | 2023 | Orgovyx |
| Dova Pharmaceuticals | $14.99 | 2021 | |
| Telix Pharmaceuticals | $14.88 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.74 | 2023 | |
| Pfizer INC. | $14.70 | 2023 | |
| Alexion Pharmaceuticals, INC. | $13.47 | 2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.86 | 2021 | |
| Seagen INC. | $12.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $6.91 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacie Schuerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.